Even though effective when activating point mutations in the SET domain are driving lymphomas [57,58] or in the background of tumours harbouring other epigenetic perturbations [59], targeting the catalytic activity of EZH2 has thus far failed to elicit the expected response in a number of other malignancies [60,61]. This evidence concerns the gene EZH2 and lymphoma.